Inovio Pharmaceuticals (INO) Cash & Equivalents (2010 - 2026)

Inovio Pharmaceuticals has reported Cash & Equivalents for 17 years, with the latest figure at $26.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 34.18% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.3 million (down 34.18% YoY) and the FY2025 annual result came in at $44.3 million, down 32.73% from the prior year.
• Cash & Equivalents retreated to $26.3 million in Q1 2026 per INO's latest filing, from $44.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $65.8 million in Q4 2024 and troughed at $14.3 million in Q4 2023.
• A 5-year average of $35.0 million and a median of $34.4 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 69.11% in 2023, then soared 359.88% in 2024.
• Over 5 years, Cash & Equivalents stood at $46.3 million in 2022, then slumped by 69.11% to $14.3 million in 2023, then jumped by 359.88% to $65.8 million in 2024, then tumbled by 32.73% to $44.3 million in 2025, then plunged by 40.66% to $26.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $26.3 million, $44.3 million, and $36.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.